Bio-Techne Corp. Stock
Bio-Techne Corp. Stock
Bio-Techne Corp. gained 1.790% today.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 60 € shows a positive potential of 34.53% compared to the current price of 44.6 € for Bio-Techne Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Bio-Techne Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Bio-Techne Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Techne Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Techne Corp. | 1.790% | -10.442% | -18.165% | -19.640% | -10.800% | -33.433% | - |
| Bio-Rad Labs Inc. A | 1.210% | 0.387% | 8.106% | 1.434% | -9.500% | -48.782% | -50.128% |
| Neogen Corp. | -3.070% | -4.762% | -11.602% | -6.433% | 30.081% | - | - |
| CONMED Corp. | 0.000% | -8.092% | -9.143% | -41.111% | -9.143% | -62.367% | -69.423% |
Comments
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Wells Fargo & Company from $70.00 to $76.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for TECH provided by MarketBeat